References
- Copier J, Dalgleish A. Whole-cell vaccines: A failure or a success waiting to happen?. Curr Opin Mol Ther 2010; 12:14 - 20; PMID: 20140812
- Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, et al. Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009; 45:1424 - 31; http://dx.doi.org/10.1016/j.ejca.2008.12.017; PMID: 19167214
- Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 2007; 25:Suppl 2 B35 - 46; http://dx.doi.org/10.1016/j.vaccine.2007.06.041; PMID: 17916462
- Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011; 29:8501 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.09.012; PMID: 21933695
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
- Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for Cancer Vaccine Development. J Biomed Biotechnol 2010: 13 p.
- Datamonitor. Dendreon Corporation PharmaVitae Emerging Biopharma Company Analysis, 2012. www.datamonitor.com
- FDA. FDA Prescribing Information for Provenge, 2010. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Approved-Products/UCM210031.pdf. Accessed: April 12, 2012.
- Sims RB. Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2011; Available online 25 November 2011 at http://www.sciencedirect.com/science/article/pii/S0264410X11018548. Accessed on April 11, 2012.
- Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61:639 - 47; http://dx.doi.org/10.1016/j.eururo.2011.10.027; PMID: 22036643
- Datamonitor. Pipeline Insight: Therapeutic Cancer Vaccines, 2009. www.datamonitor.com
- Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008; 20:286 - 95; http://dx.doi.org/10.1016/j.smim.2008.09.006; PMID: 18951039
- Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther 2007; 82:734 - 9; http://dx.doi.org/10.1038/sj.clpt.6100369; PMID: 17898707
- Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, et al. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 2011; 60:1127 - 35; http://dx.doi.org/10.1007/s00262-011-0985-7; PMID: 21479639
- Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22:457 - 72; http://dx.doi.org/10.1038/cr.2012.13; PMID: 22357481
- Nishizawa S, Hirohashi Y, Torigoe T, et al. A novel tumor-associated antigen, DNAJB8 is highly expressed in cancer stem-like cells / cancer initiating cells of renal cell carcinoma, and is potent target for immunotherapy. J Urol 2012; •••:187
- McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16:483 - 9; http://dx.doi.org/10.1038/nm.2112; PMID: 20228816
- Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011; 2:240 - 52; http://dx.doi.org/10.1038/ncomms1239; PMID: 21407206
- Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073 - 81; http://dx.doi.org/10.1093/carcin/bgp127; PMID: 19468060
- Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, et al. Combination therapy for renal cell cancer: what are possible options?. Oncology 2011; 81:220 - 9; http://dx.doi.org/10.1159/000333470; PMID: 22085914
- Datamonitor. Therapy area series: Product Profiles. Prostate Cancer 2011. www.datamonitor.com
- National Comprehensive Cancer Network. Guideline of treatment of prostate cancer, 2011; Available from: http://www.nccn.org/professionals/physician_ gls/pdf/prostate.pdf Accessed on April 13, 2012.
- Solomon B, Bunn PA Jr.. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 2007; 25:217 - 25; http://dx.doi.org/10.1080/07357900701206281; PMID: 17612931
- Pfisterer JS, Berek A, Casado B, Cwiertka K, Pinter T, Pluzanska A, et al. Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) trial. J Clin Oncol 2011; 29
- Schmidt C. Ovarian cancer treatments on the horizon. J Natl Cancer Inst 2011; 103:1284 - 5; http://dx.doi.org/10.1093/jnci/djr343; PMID: 21852261
- Yervoy FDA. (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS) - Severe Immune-Mediated Adverse Reactions, 2011; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249770.htm Accessed on April 13, 2012.
- Datamonitor. Pipeline Insight: Small Molecule Targeted Cancer Therapies, 2010. www.datamonitor.com
- FDA. Guidance for Industry: Co-development of Two or More Unmarketed Investigational Drugs for Use in Combination, 2010; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf
- Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90:85 - 94; http://dx.doi.org/10.1038/icb.2011.100; PMID: 22124371
- Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
- Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151 - 60; http://dx.doi.org/10.1038/nrclinonc.2010.223; PMID: 21364688
- Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14:529 - 37; http://dx.doi.org/10.1016/j.cbpa.2010.06.170; PMID: 20643572
- Datamonitor. PharmaVitae Emerging Technologies Series: New Antibody-Based Technologies, 2011. www.datamonitor.com
- Roche. Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer, 2011; Available from: http://www.roche.com/media/media_releases/med-cor-2011-12-08.htm Accessed on April 14, 2012.
- Zelboraf EMA. 2012; Available from: http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/002409/human_med_001544.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp Accessed on April 14, 2012.
- FDA. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer, 2011; Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm268241.htm Accessed on April 13, 2012.
- Clinicaltrials.gov search, 2012; Available from: http://www.clinicaltrials.gov Accessed on 11, April 2012.
- Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27:129 - 39; http://dx.doi.org/10.1038/nbt0209-129; PMID: 19204689
- EMA. Scientific advice and protocol assistance, 2012; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/03/WC500124212.pdf Accessed on April 13, 2012.
- Ark Therapeutics. Cerepro (sitimagene ceradenovec) – treatment for brain cancer (malignant glioma). Ark Therapeutics, 2009; Available from: http://www.arktherapeutics.com/main/products.php?content=products_cerepro Accessed on April 10, 2012.
- Cerepro EMA. 2007; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128&source=homeMedSearch&category=human&keyword=cerepro&isNewQuery=true. Accessed on April 14, 2012.
- Advexin EMA. 2008; Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000919/wapp/Initial_authorisation/human_wapp_000042.jsp&mid=WC0b01ac058001d128&source=homeMedSearch&category=human Accessed on April 14, 2012.
- EMA. EMA/CHMP/775076/2009: Withdrawal assessment report for Oncophage. 2009; Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Application_withdrawal_assessment_report/2010/03/WC500075459.pdf Accessed on April 13, 2012.
- Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48:237 - 42; http://dx.doi.org/10.1016/j.ejca.2011.09.018; PMID: 22030452
- Bakacs T, Mehrishi JN, Szabó M, Moss RW. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacological Research. 2012; Available from: http://www.sciencedirect.com/science/article/pii/S1043661812000643 Accessed on April 13, 2012.
- EMA. CHMP/EWP/433478/2010: Need to revise the guideline on the evaluation of anticancer medicinal products in man. 2010; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000406.jsp&mid=WC0b01ac0580034cf3 Accessed on April 14, 2012.
- EMA. EMEA/CHMP/BWP/271475/2006: Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer. 2008; Available from www.ema.europa.eu Accessed on April 12, 2012.
- EMA. CHMP/410869/06: Human cell-based medicinal products. 2008; Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/general/general_content_000405.jsp&mid=WC0b01ac058002958a Accessed on April 14, 2012.
- EMA. EMA/CAT/CPWP/686637/2011: Committee for Advanced Therapies (CAT) Draft guideline on the risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products. 2011; Available from www.ema.europa.eu Accessed on April 12, 2012.
- EMA. EMEA/CHMP/GTWP/587488/2007 Rev. 1: Committee for the Medicinal Products for Human Use (CHMP) Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adeno-associated viral vectors. 2007; Available from www.ema.europa.eu Accessed on April 12, 2012.
- EMA. EMEA/CHMP/VEG/134716/2004: Adjuvants in vaccines for human use. 2005; Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/general/general_content_000407.jsp&mid=WC0b01ac 058002958b&jsenabled=true Accessed on April 14, 2012.
- EMA. EMEA/CHMP/VWP/244894/2006: Explanatory note on immunomodulators for the guideline on adjuvants in vaccines for human use. 2006; Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/general/general_content_000407.jsp&mid=WC0b01ac 058002958b&jsenabled=true Accessed on April 14, 2012.
- EMA. EMEA/CHMP/VWP/164653/05: Clinical evaluation of new vaccines. 2007; Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/general/general_content_000407.jsp&mid=WC0b01ac 058002958b&jsenabled=true Accessed on April 14, 2012.
- Oh S. Cell-Based Medicinal Products for Global Market: FDA Perspectives CAT-ESGCT Workshop ESGCT Annual Meeting, Brighton, UK. 2011; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Presentation/2012/02/WC500122168.pdf Accessed on April 3, 2012.
- Witten C. FDA and Cancer Vaccine Development. 2008; Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/newsevents/ workshopsmeetingsconferences/ucm102978.pdf Accessed on April 11, 2012.
- FDA. Code of Federal Regulations. Title 21 Food and Drugs. Part 314.126. 2008; Available from: http://edocket.access.gpo.gov/cfr_2008/ aprqtr/pdf/21cfr314.126.pdf Accessed on April 3, 2012.
- FDA. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. 2007; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf Accessed on April 3, 2012.
- Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364:1087 - 9; http://dx.doi.org/10.1056/NEJMp1100548; PMID: 21428763
- Coutant D, Riggs D, Hoffman EV. Substantial Evidence: When Is a Single Trial Sufficient for Approval and Promotion?. Drug Inf J 2011; 45:253 - 63; http://dx.doi.org/10.1177/009286151104500306
- Biovest. Biovest. 2012; Available from: www.biovest.com Accessed on April 13, 2012.
- Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. Int J Oncol 2010; 36:1341 - 53; http://dx.doi.org/10.3892/ijo_00000619; PMID: 20428757
- FDA. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. 2011; Available from: http://www.fda.gov/downloads/ biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf Accessed on April 11, 2012.
- Egawa K. Immuno-cell therapy of cancer in Japan. Anticancer Res 2004; 24:5C 3321 - 6; PMID: 15515427
- Heike Y. Cellular therapies in Japan. 2010; Available from: http://www.google.co.uk/#hl=en&site=&source=hp&q=heike+and+cell+therapies+in+japan&oq=heike+and+cell+therapies+in+japan&aq=f&aqi=&aql=&gs_l=hp.3...1279l12964l0l13322l55l55l11l0l0l0l125l2622l41j2l43l0.frgbld.&bav=on.2,or.r_gc.r_pw.,cf.osb&fp=24a658667a23338a&biw=1344&bih=658. Accessed on April 11, 2012.
- Deloitte. Medical tourism: consumers in search of value. 2008; Available from: http://www.deloitte.com/assets/Dcom-unitedStates/Local%20Assets/Docume nts/ us_chs_MedicalTourismStudy(3).pdf Accessed on April 15, 2012.
- Maekawa T, Kimura S, Kasai Y. Development of Novel Advanced Cell and Gene Therapy and GMP-Controlled Cell Processing. JMAJ 2005; 48:81 - 4
- Narita M. Current status of Current Japanese Regulation and Development of Biologics. 2011; Available from: http://www.pmda.go.jp/english/past/2009bio_sympo/file/Keynote_Speech_Narita_(PMDA).pdf Accessed on April 13, 2012.
- Landsdell M. Innovative drug discovery in emerging markets. Business Insights, 2011.
- Hong S. Korean perspective on biologics regulation. 2008; Available from: http://www.pmda.go.jp/english/past/pdf/06.Dr.Hong.pdf Accessed on April 13, 2012.
- KFDA. Recent trends and Korea's cases in the development of gene therapy products KFDA. 2008; Available from: http://www.bioin.or.kr/upload.do?cmd=download&seq=7676&bid=industry. Accessed on April 5, 2012.
- Cancer therapy China. Gene Therapy (Gendicine). 2009; Available from: http://www.cancertherapychina.com/index.php?option=com_content&view=article&id=84&Itemid=23 Accessed on April 10, 2012.
- Datamonitor. Stakeholder Opinions: Gene Therapy. Gene therapy to deliver after 20 years of clinical development, 2009. www.datamonitor.com
- Datamonitor. Oncology Market Access in China Market bolstered by rising incidence and improved regulatory environment, 2011. www.datamonitor.com
- Schneider CK, Schäffner-Dallmann G. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 2008; 7:893 - 9; http://dx.doi.org/10.1038/nrd2728; PMID: 18974748
- Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388 - 97; http://dx.doi.org/10.1093/jnci/djq310; PMID: 20826737
- Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al, Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1 - 15; http://dx.doi.org/10.1097/01.cji.0000211341.88835.ae; PMID: 17198079
- Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology—analysis of host and tumor factors for personalized medicine Nature Rev. Clin Oncol 2011; 8:711 - 9
- van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453:417 - 31; http://dx.doi.org/10.1007/s00428-008-0665-y; PMID: 18802721
- Di Lorenzo G, Buonerba C. Kidney cancer: Overall Survival is an unsuitable primary clinical endpoint. Nature Urology 2010; 7:367 - 8; http://dx.doi.org/10.1038/nrurol.2010.84
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
- Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624; PMID: 19934295
- NICE. Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document. 2008; Available at: http://www.nice.org.uk/guidance/index.jsp?action=article&o=41473 Accessed on April 13, 2012.
- Garau M, Shah K, Towse A, Wang Q. Assessment and appraisal of oncology medicines: does NICE’s approach include all relevant elements? What can be learnt from international HTA experiences? Report for the Pharmaceutical Oncology Initiative Group (POI). 2009; Available from: http://www.ohe.org/publications/article/assessment-and-appraisal-of-oncology-medicines-33.cfm Accessed on April 13, 2012.
- Gomella L, Nabhan C, DeVries T, Whitmore J, Frohlich M. Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cryopreserved cell. J Urol 2012; 187:E278 - 9; http://dx.doi.org/10.1016/j.juro.2012.02.765
- Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674 - 81; http://dx.doi.org/10.1200/JCO.2005.13.011; PMID: 16170175
- DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272 - 7; http://dx.doi.org/10.1038/clpt.2009.295; PMID: 20130567
- Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60:780 - 7; http://dx.doi.org/10.1136/gut.2010.221127; PMID: 21209123
- Nexavar EMA. 2012; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000690/human_med_000929.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true Accessed on April 15, 2012.